Trial design and oversight
This was a prospective, multicenter, randomized, open-label, noninferiority, 96-week trial comparing switch to long-acting therapy versus maintaining daily oral therapy in… [+23384 chars]
Read Full Story
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
Posted on November 3, 2025 at 